| |
|
- Click on the title
of each paper to access MedLine abstract at NLM site Saif MW, Longo WL, Israel G. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. Clin Colorectal Cancer. 2008 Mar;7(2):144-8. Duffy A, Shia J, Huitzil-Melendez FD, Fong Y, O'Reilly EM. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.Clin Colorectal Cancer. 2008 Mar;7(2):140-3. Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK, Lee JS. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Med Oncol. 2008 May 22Taylor I. Adjuvant chemotherapy after resection of liver metastases from colorectal cancer. Eur J Cancer. 2008 Jun;44(9):1198-201. Cho HJ, Kim SJ, Kim SY, Han HS, Hong YS, Kim SH, Lim SB, Jung KH, Chang HJ, Hong EK. Pathologic complete response after palliative 3rd line chemotherapy with capecitabine alone in metastatic colorectal cancer. Cancer Chemother Pharmacol. 2008 May 7.Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A, Boisdron-Celle M. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008 May 1;26(13):2099-105. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008 Apr 23;299(16):1914-21.Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008 Apr 20;26(12):2013-9. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008 Apr 20;26(12):2006-12.Adam R, Wicherts DA, de Haas RJ, Aloia T, Lévi F, Paule B, Guettier C, Kunstlinger F, Delvart V, Azoulay D, Castaing D. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008 Apr 1;26(10):1635-41. Pulitanò C, Arru M, Catena M, Guzzetti E, Vitali G, Ronzoni M, Venturini M, Villa E, Ferla G, Aldrighetti L. Results of preoperative hepatic arterial infusion chemotherapy in patients undergoing liver resection for colorectal liver metastases. Ann Surg Oncol. 2008 Jun;15(6):1661-9.Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008 Mar 22;371(9617):1007-16. Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, Maughan TS, Van Cutsem E, Rougier P, Mitry E, Schubert U, Köhne CH. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol. 2008 Mar 20;26(9):1443-51.Morris M, Platell C, Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res. 2008 Mar 1;14(5):1413-7. Wanebo HJ, DiSiena M, Begossi G, Belliveau J, Gustafson E. Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum. Ann Surg Oncol. 2008 Apr;15(4):1107-16Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, Cormier JN. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol. 2008 Mar;19(3):577-82. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008 Mar 22;371(9617):1007-16 Morris M, Platell C, Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res. 2008 Mar 1;14(5):1413-7. Jackson C, Cunningham D. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer. Eur J Cancer. 2008 Mar;44(5):652-62.Zlobec I, Vuong T, Compton CC, Lugli A, Michel RP, Hayashi S, Jass JR. Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. Br J Cancer. 2008 Jan 29;98(2):450-6. de la Torre A, García-Berrocal MI, Arias F, Mariño A, Valcárcel F, Magallón R, Regueiro CA, Romero J, Zapata I, de la Fuente C, Fernández-Lizarbe E, Vergara G, Belinchón B, Veiras M, Molerón R, Millán I. Preoperative chemoradiotherapy for rectal cancer: randomized trial comparing oral uracil and tegafur and oral leucovorin vs. intravenous 5-fluorouracil and leucovorin. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):102-10.Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado RG, Hogan N, Peeters M. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol. 2008 Jan;19(1):92-8. Petrioli R, Pascucci A, Francini E, Marsili S, Fiaschi AI, Civitelli S, Tanzini G, Battistelli S, Lorenzi M, Roviello F, Francini G; Multidisciplinary Oncology Group on Gastrointestinal Tumors. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors. Anticancer Drugs. 2008 Jan;19(1):91-6. Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin Ther. 2007 Oct;29(10):2256-67.Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, Van Hazel G, Salek T, Wolf M, Devercelli G, Woolley M, Amado RG. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer. 2007 Dec 3;97(11):1469-74. Epub 2007 Nov 27. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007 Nov 15;357(20):2040-8.Craven I, Crellin A, Cooper R, Melcher A, Byrne P, Sebag-Montefiore D. Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. Br J Cancer. 2007 Nov 19;97(10):1333-7. Epub 2007 Nov 6. Cappuzzo F, Finocchiaro G, Rossi E, Jänne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol. 2007 Oct 31; [Epub ahead of print]Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007 Oct 20;25(30):4779-86. Tappenden P, Jones R, Paisley S, Carroll C. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer. 2007 Nov;43(17):2487-94. Epub 2007 Oct 1. Review.Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, Radosevic-Jelic L, Piérart M, Calais G; European Organisation for Research and Treatment of Cancer Radiation Oncology Group. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007 Oct 1;25(28):4379-86. Barone C, Nuzzo G, Cassano A, Basso M, Schinzari G, Giuliante F, D'Argento E, Trigila N, Astone A, Pozzo C. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.Br J Cancer. 2007 Oct 22;97(8):1035-9. Epub 2007 Sep 25. Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer. 2007 Oct 22;97(8):1021-7. Epub 2007 Sep 25.Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol. 2007 Oct;8(10):898-911. Epub 2007 Sep 20. de la Torre A, García-Berrocal MI, Arias F, Mariño A, Valcárcel F, Magallón R, Regueiro CA, Romero J, Zapata I, de la Fuente C, Fernández-Lizarbe E, Vergara G, Belinchón B, Veiras M, Molerón R, Millán I. Preoperative chemoradiotherapy for rectal cancer: randomized trial comparing oral uracil and tegafur and oral leucovorin vs. intravenous 5-fluorouracil and leucovorin. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):102-10. Epub 2007 Sep 14.Pieterse AH, Stiggelbout AM, Baas-Thijssen MC, van de Velde CJ, Marijnen CA. Benefit from preoperative radiotherapy in rectal cancer treatment: disease-free patients' and oncologists' preferences. Br J Cancer. 2007 Sep 17;97(6):717-24. Law CC, Fu YT, Chau KK, Choy TS, So PF, Wong KH. Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer. Dis Colon Rectum. 2007 Dec;50(12):2180-7.Park IJ, Kim HC, Yu CS, Kim TW, Jang SJ, Kim JC. Effect of adjuvant radiotherapy on local recurrence in stage II rectal cancer. Ann Surg Oncol. 2008 Feb;15(2):519-25. Epub 2007 Oct 25. Vormittag L, Kornek GV, Gruhsmann B, Lenauer A, Foger A, Depisch D, Lang F, Scheithauer W. UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis. Anticancer Drugs. 2007 Jul;18(6):709-12. des Guetz G, Mariani P, Cucherousset J, Benamoun M, Lagorce C, Sastre X, Le Toumelin P, Uzzan B, Perret GY, Morere JF, Breau JL, Fagard R, Schischmanoff PO. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res. 2007 Jul-Aug;27(4C):2715-9.
Dy GK,
Krook JE, Green EM, Sargent DJ, Delaunoit T, Morton RF,
Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pockaj
BA, Sticca RP, Alberts SR, Pitot HC 4th, Goldberg RM;
Intergroup N9741.
Impact of complete response to chemotherapy on overall
survival in advanced colorectal cancer: results from
Intergroup N9741.
J Clin Oncol. 2007 Aug 10;25(23):3469-74.
de
Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E,
Cervantes A, Figer A, Lledo G, Flesch M, Mineur L, Carola E,
Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C,
Andre T, Tabah-Fisch I, Tournigand C.
Reintroduction of oxaliplatin is associated with improved
survival in advanced colorectal cancer.
J Clin Oncol. 2007 Aug 1;25(22):3224-9.
Koopman
M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de
Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van
Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH,
Werter MJ, Mol L, Dalesio O, Punt CJ.
Sequential versus combination chemotherapy with capecitabine,
irinotecan, and oxaliplatin in advanced colorectal cancer
(CAIRO): a phase III randomised controlled trial.
Lancet. 2007 Jul 14;370(9582):135-42.
Punt CJ,
Buyse M, Kohne CH, Hohenberger P, Labianca R, Schmoll HJ,
Pahlman L, Sobrero A, Douillard JY.
Endpoints in adjuvant treatment trials: a systematic review
of the literature in colon cancer and proposed definitions
for future trials. J Natl Cancer Inst. 2007
Jul 4;99(13):998-1003.
Porschen
R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W,
Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W,
Schmoll HJ; AIO Colorectal Study Group.
Phase III study of capecitabine plus oxaliplatin compared
with fluorouracil and leucovorin plus oxaliplatin in
metastatic colorectal cancer: a final report of the AIO
Colorectal Study Group. J Clin Oncol. 2007 Sep 20;25
(27):4217-23.
Rankovic VI, Masirevic VP, Pavlov MJ, Ceranic MS, Milenkovic MG, Simic AP, Kecmanovic DM. Hemodynamic and cardiovascular problems during modified hyperthermic intraperitoneal perioperative chemotherapy. Hepatogastroenterology. 2007 Mar;54(74):364-6.
Morris E, Maughan NJ, Forman D, Quirke P. Who to treat with adjuvant therapy in Dukes B/Stage II colorectal cancer? - The need for high quality pathology. Gut. 2007 May 9; Muss HB, Biganzoli L, Sargent DJ, Aapro M. Adjuvant therapy in the elderly: making the right decision. J Clin Oncol. 2007 May 10;25(14):1870-5. Review. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007 May 1;25(13):1670-6. Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist. 2007 Apr;12(4):443-50. Kinoshita M, Kodera Y, Hibi K, Nakayama G, Inoue T, Ohashi N, Ito Y, Koike M, Fujiwara M, Nakao A. Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy. Anticancer Res. 2007 Mar-Apr;27(2):851-6. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist. 2007 Mar;12(3):356-61. Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Matsui N, Nakamura M, Nakasaki H, Makuuchi H. Sensitivity to CPT-11 and platinum derivatives of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep. 2007 May;17(5):1027-32
Tappenden P, Jones R, Paisley S, Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess. 2007 Mar;11(12):1-146. Shivnani AT, Small W Jr, Stryker SJ, Kiel KD, Lim S, Halverson AL, Talamonti MS. Preoperative chemoradiation for rectal cancer: results of multimodality management and analysis of prognostic factors. Am J Surg. 2007 Mar;193(3):389-93
Bauhofer A, Plaul U, Torossian A, Koller M, Stinner B, Celik I, Sitter H, Greger B, Middeke M, Schein M, Wyatt J, Nystrom PO, Hartung T, Rothmund M, Lorenz W. Perioperative prophylaxis with granulocyte colony-stimulating factor (G-CSF) in high-risk colorectal cancer patients for an improved recovery: A randomized, controlled trial. Surgery. 2007 Apr;141(4):501-10 Reddy N, Yu J, Fakih MG.Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy. Clin Colorectal Cancer. 2007 Jan;6(5):362-6. Damianovich D, Adena M, Tebbutt NC. Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis. Br J Cancer. 2007 Feb 26;96(4):546-50. Kopec JA, Yothers G, Ganz PA, Land SR, Cecchini RS, Wieand HS, Lembersky BC, Wolmark N. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol. 2007 Feb 1;25(4):424-30. Thornton AD, Ravn P, Winslet M, Chester K. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br J Surg. 2006 Dec;93(12):1456-63. Review.
Hochster HS.
Bevacizumab in combination with chemotherapy: first-line
treatment of patients with metastatic colorectal cancer. Norum J. Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis. J Chemother. 2006 Oct;18(5):532-7. Warusavitarne J, Schnitzler M. The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis. 2006 Nov 16; D'Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, Dematteo RP, Fong Y, Kemeny N, Blumgart LH, Saltz LB. Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study. Ann Surg Oncol. 2006 Nov 11;
Prosnitz RG, Patwardhan MB, Samsa GP,
Mantyh CR, Fisher DA, McCrory DC, Cline KE, Gray RN, Morse MA.
Quality measures for the use of adjuvant chemotherapy and radiation therapy in
patients with colorectal cancer: a systematic review. Eggington S, Tappenden P, Pandor A, Paisley S, Saunders M, Seymour M, Sutcliffe P, Chilcott J. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer. 2006 Nov 6;95(9):1195-201.
Benoist S, Brouquet A,
Penna C, Julie C, El Hajjam M, Chagnon S, Mitry E, Rougier P,
Nordlinger B.
Complete response of colorectal liver metastases after
chemotherapy: does it mean cure? Chung KY, Kelsen D. Adjuvant Therapy for Stage II Colorectal Cancer: Who and with What? Curr Treat Options Gastroenterol. 2006 Jun;9(3):272-80. Oki E, Kakeji Y, Yoshida R, Ikeda K, Nishida K, Koga T, Egashira A, Tokunaga E, Morita M, Baba H, Maehara Y. [A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):] Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:138-43. Japanese Yoshimatsu K, Umehara A, Ishibashi K, Yokomizo H, Yoshida K, Fujimoto T, Watanabe K, Ogawa K. Indication and efficacy of adjuvant chemotherapy with oral fluoropyrimidines for dukes' B colorectal cancer. Anticancer Res. 2006 Jul-Aug;26(4B):3089-93. Capirci C, Rubello D, Chierichetti F, Crepaldi G, Fanti S, Mandoliti G, Salviato S, Boni G, Rampin L, Polico C, Mariani G. Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR Am J Roentgenol. 2006 Aug;187(2):W202-8. Knutsen A, Adell G, Sun XF. Inflammatory infiltration, fibrosis, necrosis and mucinous content in relation to clinicopathological and molecular factors in rectal cancers with or without preoperative radiotherapy. Oncol Rep. 2006 Aug;16(2):321-7. Ward SE, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour MT. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer. 2006 Jul 3;95(1):27-34. Pelz JO, Doerfer J, Dimmler A, Hohenberger W, Meyer T. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations. BMC Cancer. 2006 Jun 22;6:162. Sobrero A. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal. Lancet Oncol. 2006 Jun;7(6):515-6. Roels S, Duthoy W, Haustermans K, Penninckx F, Vandecaveye V, Boterberg T, De Neve W. Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1129-42. Crozier JE, McKee RF, McArdle CS, Angerson WJ, Anderson JH, Horgan PG, McMillan DC. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer. 2006 Jun 19;94(12):1833-6. Vulto AJ, Lemmens VE, Louwman MW, Janssen-Heijnen ML, Poortmans PH, Lybeert ML, Coebergh JW. The influence of age and comorbidity on receiving radiotherapy as part of primary treatment for cancer in South Netherlands, 1995 to 2002. Cancer. 2006 Jun 15;106(12):2734-42.
Burton S, Brown G, Daniels I, Norman
A, Swift I, Abulafi M, Wotherspoon A, Tait D.
MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid,
and upper rectum: treatment with radiotherapy and chemotherapy. Goto A, Yamada Y, Yasui H, Kato K, Hamaguchi T, Muro K, Shimada Y, Shirao K. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol. 2006 Jun;17(6):968-73. Bakx R, Emous M, Legemate DA, Zoetmulder FA, van Tienhoven G, Bemelman WA, van Lanschot JJ. Harm and benefits of short-term pre-operative radiotherapy in patients with resectable rectal carcinomas. Eur J Surg Oncol. 2006 Jun;32(5):520-6.
Melichar B, Voboril Z, Cerman J Jr,
Melicharova K, Mergancova J, Voboril R, Jandik
P.
Survival of patients with colorectal cancer liver metastases
treated by regional chemotherapy. Assenat E, Duffour J, Ychou M. [Irinotecan for the treatment of metastatic colorectal cancer] Bull Cancer. 2006 May 1;93(5):507-15. Review. French.
Zheng H, Chen JZ, Liao
WJ, Luo RC.
[Efficacy of Avastin in combination with irinotecan for
metastatic colorectal cancer] Crozier JE, McKee RF, McArdle CS, Angerson WJ, Anderson JH, Horgan PG, McMillan DC. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer. 2006 Jun 19;94(12):1833-6. Hu JB, Sun XN, Yang QC, Xu J, Wang Q, He C. Three-dimensional conformal radiotherapy combined with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer. World J Gastroenterol. 2006 Apr 28;12(16):2610-4.
Sturm I, Rau B, Schlag
PM, Wust P, Hildebrandt B, Riess H, Hauptmann S, Dorken B,
Daniel PT.
Genetic dissection of apoptosis and cell cycle control in
response of colorectal cancer treated with preoperative
radiochemotherapy.
Neugut AI, Matasar M,
Wang X, McBride R, Jacobson JS, Tsai WY, Grann VR, Hershman DL.
Duration of adjuvant chemotherapy for colon cancer and survival
among the elderly. Hasegawa S, Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tajima T, Nakasaki H, Makuuchi H. Long-term survival and tumor 5-FU sensitivity in patients with stage IV colorectal cancer and peritoneal dissemination. Oncol Rep. 2006 May;15(5):1185-90. Feliu J, Salud A, Escudero P, Lopez-Gomez L, Bolanos M, Galan A, Vicent JM, Yubero A, Losa F, De Castro J, de Mon MA, Casado E, Gonzalez-Baron M. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer. 2006 Apr 10;94(7):969-75. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006 Mar 27;94(6):798-805.
Kemeny NE, Niedzwiecki
D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC,
Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ.
Hepatic arterial infusion versus systemic therapy for hepatic
metastases from colorectal cancer: a randomized trial of
efficacy, quality of life, and molecular markers (CALGB 9481).
Ortholan C, Francois
E, Thomas O, Benchimol D, Baulieux J, Bosset JF, Gerard JP.
Role of radiotherapy with surgery for T3 and resectable T4
rectal cancer: evidence from randomized trials. Homsi J, Garrett CR. Hepatic arterial infusion of chemotherapy for hepatic metastases from colorectal cancer. Cancer Control. 2006 Jan-Feb;13(1):42-7.
Vincenzi B, Santini D, Russo A,
Silletta M, Gavasci M, Battistoni F, Di Cuonzo G, Rocci L, Gebbia N, Tonini G.
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer
treatment in advanced colorectal cancer patients.
Kemeny NE, Niedzwiecki D, Hollis DR,
Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang
C, Mayer RJ.
Hepatic Arterial Infusion Versus Systemic Therapy for Hepatic Metastases From
Colorectal Cancer: A Randomized Trial of Efficacy, Quality of Life, and
Molecular Markers (CALGB 9481). Correale P, Cusi MG, Micheli L, Nencini C, Del Vecchio MT, Torino F, Aquino A, Bonmassar E, Francini G, Giorgi G. Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience. Invest New Drugs. 2006 Feb 24; Andre T, Tournigand C, Achille E, Tubiana-Mathieu N, Lledo G, Raoul Y, Carola E, Flesch M, Muron T, Boutan-Laroze A, Guerin Meyer V, Boaziz C, Maigre M, Ganem G, Mousseau M, Mounedji-Boudiaf L, de Gramont A. [Adjuvant treatment of colon cancer MOSAIC study's main results Bull Cancer. 2006 Feb 1;93 Suppl 1:S5-9. French. de Kort SJ, Willemse PH, Habraken JM, de Haes HC, Willems DL, Richel DJ. Quality of life versus prolongation of life in patients treated with chemotherapy in advanced colorectal cancer: A review of randomized controlled clinical trials. Eur J Cancer. 2006 Feb 13;
Glynne-Jones R, Grainger J, Harrison
M, Ostler P, Makris A.
Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in
rectal cancer: should we be more cautious?
Jensen SA, Lonborg JT, Sorensen JB.
Benefits and risks of palliative capecitabine based therapy to elderly patients
with advanced colorectal cancer: Danish single centre experiences. Park YA, Sohn SK, Seong J, Baik SH, Lee KY, Kim NK, Cho CW. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol. 2006 Feb 1;93(2):145-50. Konski A, Hoffman J, Sigurdson E, Haluszka O, Engstrom P, Cheng JD, Cohen SJ, Watson JC, Eisenberg D, McGarrity E, Freedman G, Meropol NJ. Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience. Semin Oncol. 2005 Dec;32(6 Suppl 9):S63-7. Marshall J. The role of bevacizumab as first-line therapy for colon cancer. Semin Oncol. 2005 Dec;32(6 Suppl 9):S43-7. Review.
Masi G, Cupini S, Marcucci L, Cerri E, Loupakis F,
Allegrini G, Brunetti IM, Pfanner E, Viti M, Goletti O, Filipponi F, Falcone A.
Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables
surgical resection of metastases in patients with initially unresectable
metastatic colorectal cancer.
Toyokawa A, Tsujimura T, Hamabe Y,
Sato S, Mukubou H, Wakahara T, Kaji M, Tsukamoto T, Wakita K, Onishi N, Ishida
T, Watanabe A, Fujiwara H, Mukai H.
[Clinical study of ambulatory patient cancer chemotherapy for advanced
colorectal cancer] Popov I, Jelic S, Krivokapic Z, Micev M, Babic D, Zdrale Z. What is the best sequence of chemotherapy in advanced colorectal cancer? Final results of a five-arm study. Chemotherapy. 2006;52(1):20-2. Duff SE, Jeziorska M, Rosa DD, Kumar S, Haboubi N, Sherlock D, O'Dwyer ST, Jayson GC. Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer. 2006 Jan;42(1):112-7. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B; Swedish Rectal Cancer Trial Group. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol. 2005 Dec 1;23(34):8697-705. Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005 Dec 1;23(34):8671-8. Lim JF, Tjandra JJ, Hiscock R, Chao MW, Gibbs P. Preoperative chemoradiation for rectal cancer causes prolonged pudendal nerve terminal motor latency. Dis Colon Rectum. 2006 Jan;49(1):12-9. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005 Dec 1;23(34):8664-70. Lezoche E, Guerrieri M, Paganini AM, Baldarelli M, De Sanctis A, Lezoche G. Long-term results in patients with T2-3 N0 distal rectal cancer undergoing radiotherapy before transanal endoscopic microsurgery. Br J Surg. 2005 Dec;92(12):1546-52. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005 Dec 1;23(34):8688-96.
Zlobec I, Steele R, Compton CC.
VEGF as a predictive marker of rectal tumor response to preoperative
radiotherapy. Cancer. 2005 Dec 1;104(11):2517-21.
Bloemendaal AL, Verwaal VJ, van Ruth
S, Boot H, Zoetmulder FA.
Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of
colorectal origin: a prospective study.
Melichar B, Kohlova T,
Vesely P.
Survival after oxaliplatin therapy of irinotecan-pretreated
advanced colorectal cancer patients. Kabashima A, Sakaguchi Y, Okita K, Yamamura S, Ojima Y, Nishizaki T, Tashiro H, Matsuzaka T. [Efficacy of tegafur/uracil plus oral leucovorin therapy for advanced or recurrent colorectal cancer] Gan To Kagaku Ryoho. 2005 Nov;32(12):1935-8. Japanese. Sebag-Montefiore D, Glynne-Jones R, Falk S, Meadows HM, Maughan T. A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study. Br J Cancer. 2005 Oct 31;93(9):993-8. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH.Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study.J Clin Oncol. 2005 Oct 17; Nogue M, Salud A, Batiste-Alentorn E, Saigi E, Losa F, Cirera L, Mendez M, Campos JM, Galan A, Escudero P, Arcusa A, Manzano H, de Mendizabal EV, de Olaguer JP, Boleda M, Guasch I, Vicente P. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. Eur J Cancer. 2005 Oct;41(15):2241-9. Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tsuchiya K, Nakasaki H, Makuuchi H. Recurrence and 5-FU sensitivity of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep. 2005 Nov;14(5):1171-6. Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tsuchiya K, Nakasaki H, Makuuchi H. Recurrence and 5-FU sensitivity of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep. 2005 Nov;14(5):1165-9. Pachkoria K, Zhang H, Adell G, Jarlsfelt I, Sun XF. Significance of Cox-2 expression in rectal cancers with or without preoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):739-44. Schuell B, Gruenberger T, Kornek GV, Dworan N, Depisch D, Lang F, Schneeweiss B, Scheithauer W. Side effects during chemotherapy predict tumour response in advanced colorectal cancer. Br J Cancer. 2005 Oct 3;93(7):744-8. Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005 Sep 1;91(3):173-80.
Wong SF.
Cetuximab: an epidermal growth factor receptor monoclonal
antibody for the treatment of colorectal cancer. Saif MW. Capecitabine versus continuous-infusion 5-Fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. Clin Colorectal Cancer. 2005 Jul;5(2):89-100. Link KH, Kornmann M, Staib L, Redenbacher M, Kron M, Beger HG; Study Group Oncology of Gastrointestinal Tumors. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha. Ann Surg. 2005 Aug;242(2):178-87. Mulcahy MF, Benson AB 3rd. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther. 2005 Jul;5(7):997-1005. Shimizu D, Ishikawa T, Ichikawa Y, Togo S, Hayasizaki Y, Okazaki Y, Danenberg PV, Shimada H. Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays. Int J Oncol. 2005 Aug;27(2):371-6. Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M; gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005 Aug 1;23(22):4881-7. Kurt M, Ozkan L, Ercan I, Kahraman S, Zorluoglu A, Gurel S, Memik F, Engin K. Preoperative chemoradiotherapy in patients with locally advanced rectal cancer. Hepatogastroenterology. 2005 Jul-Aug;52(64):1095-100. Nordlinger B, Rougier P, Arnaud JP, Debois M, Wils J, Ollier JC, Grobost O, Lasser P, Wals J, Lacourt J, Seitz JF, Guimares dos Santos J, Bleiberg H, Mackiewickz R, Conroy T, Bouche O, Morin T, Baila L, van Cutsem E, Bedenne L. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial. Lancet Oncol. 2005 Jul;6(7):459-68.
Twelves C, Wong A,
Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes
A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski
P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M,
Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel
G, Zaluski J, Scheithauer W.
Capecitabine as adjuvant treatment for stage III colon cancer. Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, O'Donoghue DP, Moriarty M, Fennelly D, Sheahan K. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005 Aug;47(2):141-6. Sadahiro S, Mitomi T, Noto T, Kumada K, Hiki Y, Yamakawa T, Amano T, Oki S, Otani Y, Oka H, Takahashi T, Takemiya S, Nishiyama K, Yamamura T, Tsuchiya S, Ogawa N; Study Group on Postoperative Adjuvant Chemotherapy in Kanagawa Prefecture. [Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection] Gan To Kagaku Ryoho. 2005 Jul;32(7):997-1005. McKendrick J, Coutsouvelis J. Capecitabine: effective oral fluoropyrimidine chemotherapy. Expert Opin Pharmacother. 2005 Jul;6(7):1231-9. Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M, Micciche F, Ricci R, Morganti AG, Gambacorta MA, Maurizi F, Coco C. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):752-60. Chessin DB, Enker W, Cohen AM, Paty PB, Weiser MR, Saltz L, Minsky BD, Wong WD, Guillem JG. Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service. J Am Coll Surg. 2005 Jun;200(6):876-82; discussion 882-4. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005 Jun 1;23(16):3706-12.
Negri FV, Wotherspoon
A, Cunningham D, Norman AR, Chong G, Ross PJ.
Mucinous histology predicts for reduced fluorouracil
responsiveness and survival in advanced colorectal cancer. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005 Jun 1;23(16):3697-705. Amichetti M, Lay G, Dessi M, Orru S, Farigu R, Orru P, Farci D, Melis S; Cagliari Neuro-Oncology Group. Results of whole brain radiation therapy in patients with brain metastases from colorectal carcinoma. Tumori. 2005 Mar-pr;91(2):163-7. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005 May 20;23(15):3502-8. Motl S. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am J Health Syst Pharm. 2005 May 15;62(10):1021-32. Fernandez-Cebrian JM, Vorwald Kuborn P, Pardo de Lama M, Sanjuanbenito Dehesa A, Nevado Santos M, Pacheco Martinez PA, Fernandez-Escudero B. [Current status of the prognostic value of molecular markers in patients with colorectal cancer and the prediction of response to adjuvant therapy] Clin Transl Oncol. 2005 Apr;7(3):101-9. Aschele C, Friso ML, Pucciarelli S, Lonardi S, Sartor L, Fabris G, Urso ED, Del Bianco P, Sotti G, Lise M, Monfardini S. A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol. 2005 May 13; Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005 Jun 1;23(16):3706-12 |
